PubAg

Main content area

The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: A pilot study

Author:
Abrams-Ogg, Anthony C.G.
Source:
Canadian journal of veterinary research 2011 v.75 no.1 pp. 73-76
ISSN:
0830-9000
Subject:
Beagle, adverse effects, blood, cephalexin, disease control, dogs, lithium, neutropenia
Abstract:
This was a preliminary investigation of the use of lithium to prevent lomustine-induced myelosuppression. Four 10 to 11 kg beagles received lomustine 20 to 30 mg, PO, q3wk, with cephalexin prophylaxis. Two dogs also received lithium, 150 to 300 mg, PO, q12h. Lithium blood concentrations fluctuated in and out of therapeutic interval. Lithium was discontinued in one dog in week 13, and in the other dog in week 38, due to toxicoses. All dogs developed grade 1 to 4 neutropenia after each lomustine treatment. In dogs receiving lomustine only, platelet concentrations decreased from 274 and 293 × 10(9)/L in week 1, to 178 and 218 × 10(9)/L in weeks 38 and 13, respectively. In dogs receiving lomustine and lithium, platelet concentrations decreased from 351 and 288 × 10(9)/L in week 1, to 214 and 212 × 10(9)/L, in weeks 36 and 13, respectively. Lithium did not prevent lomustine-induced myelosuppression and had important side-effects.
Agid:
295585